This is a preview of subscription content, log in via an institution to check access.
Notes
Both conducted, at least in part, by Urovant Sciences.
References
1. Nesheim J, et al. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the United States. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PUK5, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111442
2. V CJ, et al. Cost Effectiveness of Vibegron for the Treatment of Overactive Bladder in the United States. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PUK6, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111434
Rights and permissions
About this article
Cite this article
Vibegron makes economic sense for overactive bladder in the USA. PharmacoEcon Outcomes News 880, 34 (2021). https://doi.org/10.1007/s40274-021-7792-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7792-y